Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 151 clinical trials
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia

The study will investigate in newly diagnosed CP-CML patients the efficacy of NIL frontline therapy vs IM followed by switch to NIL in the case of absence of optimal response as defined by the

  • 10 views
  • 21 Jan, 2021
  • 38 locations
DC Vaccination in CML

residual leukemia cells. Patients to be included are chronic phase bcr/abl+ CML (chronic myeloid leukemia) patients in stable cytogenetic and/or molecular remission. These patients can be included

bcr-abl protein
leukemia
tyrosine
residual tumor
remission
  • 6 views
  • 22 Jan, 2021
  • 2 locations
Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase

imatinib (Glivec®) in pretreated Philadelphia chromosome- positive (Ph+)/BCR-ABL+ CML patients in chronic phase.

imatinib
philadelphia chromosome
gleevec
interferon
leukemia
  • 11 views
  • 07 Nov, 2020
  • 1 location
Treatment Modification Based on Early Assessment of CML Patients

The investigators will check the feasibility of using early molecular response for making treatment decisions. Patients diagnosed with chronic myeloid leukemia will commence imatinib treatment

imatinib
philadelphia chromosome
nilotinib
tyrosine
philadelphia chromosome positive chronic myelogenous leukemia
  • 5 views
  • 08 Nov, 2020
  • 1 location
ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission

relapse (loss of MMR) in CML patients, who discontinue ABL tyrosine kinase inhibitor therapy (TKI) in deep molecular remission of MR4 or better (MR4.5, or MR5).

  • 22 views
  • 25 Jan, 2021
  • 48 locations
Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia

The treatment of CML and the expected survival has been revolutionised since the introduction of tyrosine kinase inhibitors (TKIs) such as nilotinib. Despite their effectiveness, these drugs

imatinib
basophils
nilotinib
potassium
tyrosine
  • 10 views
  • 07 Nov, 2020
  • 1 location
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

This randomized phase II trial studies how well ruxolitinib phosphate, and bosutnib, dasatinib, or nilotinib, work in treating patients with chronic myeloid leukemia. Chronic myeloid leukemia

  • 38 views
  • 11 May, 2021
  • 442 locations
Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy

The study is controlled and randomized in Philadelphia-positive chronic myeloid leukemia (Ph+ CML) patients with complete cytogenetic response after more than one year of imatinib therapy

interferon
imatinib
leukemia
remission
  • 8 views
  • 07 Nov, 2020
  • 1 location
Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial

The purpose of this study is to assess whether dasatinib can be discontinued without occurrence of molecular relapse in patients with chronic myeloid leukemia in chronic phase in complete

dasatinib
leukemia
remission
  • 7 views
  • 08 Nov, 2020
  • 1 location
Dasatinib Holiday for Improved Tolerability

Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment nave disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase

imatinib
nilotinib
potassium
hydroxyurea
bosutinib
  • 11 views
  • 05 Feb, 2021
  • 80 locations